Φορτώνει......
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
Background MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent preclinical data suggests the agent may have mechanisms of action that are independe...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Invest New Drugs |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer US
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4608248/ https://ncbi.nlm.nih.gov/pubmed/26123926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0269-8 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|